Zhenyang Liu

机构：Central South University, Hunan Cancer Hospital · ORCID：0009-0007-2079-1611

发表论文 54 篇 · 总被引 617 次 · h-index 14

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 40)
• Short-Wave Infrared Light-Emitting Diodes Using Colloidal CuInS 2 Quantum Dots with ZnI 2 Dual-Passivation (2024 · ACS Nano · 被引 20)
• Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Pressure-Modulated Energy Transfer Dynamics in Mn 2+ -Doped CdS/ZnS Core/Shell Quantum Dots (2025 · Journal of the American Chemical Society · 被引 18)
• Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study. (2025 · Journal of Clinical Oncology · 被引 6)